Lentiviral Infection of Mouse Bone Marrow Cells for Hematopoietic Stem Cell Transplantation

  • Cang Chen
  • Michael J. Guderyon
  • Guo Ge
  • Robert A. Clark
  • Senlin LiEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1919)


Lentiviral vectors are increasingly used as efficient gene transfer tools in the experimental and clinical gene therapy treatment of acquired and inherited genetic diseases. Hematopoietic stem cells (HSCs) are characterized by the capacity for self-renewal, as well as multi-lineage differentiation and maintenance of the lymphohematopoietic system throughout life. As such, HSC transplantation (HSCT) has proven to be a powerful therapeutic modality for the treatment of both malignant and nonmalignant disorders. Transduction of lentiviral vectors into HSCs may offer long-term stable expression of a therapeutic gene in both preclinical and clinical settings. The purpose of this chapter is to describe an optimized procedure for lentiviral transduction of mouse HSCs followed by HSCT.

Key words

Lentiviral vector Co-transfection Viral transduction Bone marrow cells Hematopoietic stem cell transplantation 



The establishment of this method was supported by a Merit Review grant (2I01BX000737) from the Department of Veterans Affairs Biomedical Laboratory Research & Development Program and by the William and Ella Owens Medical Research Foundation.


  1. 1.
    Copelan EA (2006) Hematopoietic stem-cell transplantation. N Engl J Med 354:1813–1826CrossRefGoogle Scholar
  2. 2.
    Gratwohl A, Baldomero H, Aljurf M (2010) Hematopoietic stem cell transplantation, a global perspective. JAMA 303:1617–1624CrossRefGoogle Scholar
  3. 3.
    Linton MF, Atkinson JB, Fazio S (1995) Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 267:1034–1037CrossRefGoogle Scholar
  4. 4.
    Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC (2013) Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341:1233151CrossRefGoogle Scholar
  5. 5.
    De Ravin SS, Wu X, Moir S, Anaya-Ο'Brien S, Kwatemaa N, Littel P, Theobald N, Choi U, Su L, Marquesen M (2016) Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 8:335ra357CrossRefGoogle Scholar
  6. 6.
    Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S (2013) Lentiviral hematopoietic stem cell gene therapy benefits metachromatic Leukodystrophy. Science 341:1233158CrossRefGoogle Scholar
  7. 7.
    Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C, Canale S, Lopez ID, Morena F, Calabria A (2016) Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy, an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet 388:476–487CrossRefGoogle Scholar
  8. 8.
    He W, Qiang M, Ma W, Valente AJ, Quinones MP, Wang W, Reddick RL, Xiao Q, Ahuja SS, Clark RA (2006) Development of a synthetic promoter for macrophage gene therapy. Hum Gene Ther 17:949–959CrossRefGoogle Scholar
  9. 9.
    Biju K, Zhou Q, Li G, Imam SZ, Roberts JL, Morgan WW, Clark RA, Li S (2010) Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration, a therapeutic strategy for Parkinson's disease. Mol Ther 18:1536–1544CrossRefGoogle Scholar
  10. 10.
    Biju KC, Santacruz RA, Chen C, Zhou Q, Yao J, Rohrabaugh SL, Clark RA, Roberts JL, Phillips KA, Imam SZ (2013) Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease. Neurosci Lett 535:24–29CrossRefGoogle Scholar
  11. 11.
    Chen C, Li X, Ge G, Liu J, Biju KC, Laing SD, Qian Y, Ballard C, He Z, Masliah E (2018) GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice. Sci Rep 8:5460CrossRefGoogle Scholar
  12. 12.
    Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE, Acharya SA, Ellis J, London IM, Eaves CJ (2001) Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294:2368–2371CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Cang Chen
    • 1
  • Michael J. Guderyon
    • 1
  • Guo Ge
    • 1
  • Robert A. Clark
    • 1
    • 2
  • Senlin Li
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of MedicineUT Health Science Center at San AntonioSan AntonioUSA
  2. 2.Research and Development ServiceAudie L. Murphy VA HospitalSan AntonioUSA
  3. 3.Department of PharmacologyUniversity of Texas Health San AntonioSan AntonioUSA

Personalised recommendations